Systemic Organ Communication in STEMI

Condition(s) studied

Investigational drug(s) / intervention(s)

collection of clinical data: prospectively and systematically collection of clinical research data from STEMI patients

Study summary

Despite progress in pre-hospital care, ambulance logistics, pharmacotherapy and PPCI techniques, ST-segment elevation myocardial infarction (STEMI) continues to confer a substantial burden of morbidity and mortality.

Within the STEMI population, there is a spectrum of higher and lower risk patients. The aim of this cohort study is to collect prospectively and systematically clinical research data from STEMI patients. This cohort study is an open-end observational study to identify master switches in myocardial ischemia.

Eligibility

Primary outcome measure(s)

• Left-ventricular function — 6 months
  * LV-EF \< 40% at 6 months * Δ LV-EF ≥ 5% between day 5 of hospitalization and 6 months
• Left-ventricular remodeling — 6 months
  Δ LVEDV ≥ 20% or Δ LVESV ≥ 15% between day 5 of hospitalization and 6 months
• Myocardial texture — on day 5 of hospitalization and 6 months
  * Infarct/Scar size \> 17.9% or MVO (yes) or IMH (yes) on day 5 of hospitalization or at 6 months * remote zone ΔECV between day 5 of hospitalization and 6 months
• Patency rate — 6 months
  Coronary patency rate

Trial sites (1)

More Heinrich-Heine University, Duesseldorf trials in Germany

Other trials for the same condition